Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.

Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto PA, Motti ML.

Int J Oncol. 2018 Sep;53(3):1149-1159. doi: 10.3892/ijo.2018.4457. Epub 2018 Jun 27.

2.

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M, Hansson L, Mulder TA, Adamson L, Näsman-Glaser B, Eriksson I, Heimersson K, Ryblom H, Mozaffari F, Svensson A, Gentilcore G, Österborg A, Mellstedt H.

Eur J Haematol. 2018 Jul;101(1):68-77. doi: 10.1111/ejh.13065. Epub 2018 May 22.

PMID:
29569742
3.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H.

Haematologica. 2017 Mar;102(3):562-572. doi: 10.3324/haematol.2016.151100. Epub 2016 Dec 7.

4.

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.

Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracò C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA.

Oncoimmunology. 2015 May 22;4(6):e1008842. eCollection 2015 Jun.

5.

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.

Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S.

Front Immunol. 2015 May 13;6:230. doi: 10.3389/fimmu.2015.00230. eCollection 2015. Review.

6.

Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

Ishikawa T, Wondimu Z, Oikawa Y, Gentilcore G, Kiessling R, Egyhazi Brage S, Hansson J, Patarroyo M.

Matrix Biol. 2014 Sep;38:69-83. doi: 10.1016/j.matbio.2014.06.002. Epub 2014 Jun 18.

7.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, Masucci GV, Kiessling R.

Cancer Immunol Res. 2013 Sep;1(3):158-62. doi: 10.1158/2326-6066.CIR-13-0016. Epub 2013 Aug 2. Erratum in: Cancer Immunol Res. 2013 Dec;1(6):438.

8.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.

Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA.

Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Erratum in: Cancer Immunol Immunother. 2014 Nov;63(11):1233.

PMID:
24695951
9.

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.

Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R.

J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135.

10.

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.

Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli P, Ascierto PA, Gentilcore G, Serra M, Marasco A, Tornari E, Dozin B, Pistillo MP.

Cancer Invest. 2013 Jun;31(5):336-45. doi: 10.3109/07357907.2013.793699. Epub 2013 May 3.

PMID:
23641913
11.

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.

Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA.

BMC Cancer. 2013 Jan 14;13:17. doi: 10.1186/1471-2407-13-17.

12.

Increased HOX C13 expression in metastatic melanoma progression.

Cantile M, Scognamiglio G, Anniciello A, Farina M, Gentilcore G, Santonastaso C, Fulciniti F, Cillo C, Franco R, Ascierto PA, Botti G.

J Transl Med. 2012 May 14;10:91. doi: 10.1186/1479-5876-10-91.

13.

NF-κB as potential target in the treatment of melanoma.

Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA.

J Transl Med. 2012 Mar 20;10:53. doi: 10.1186/1479-5876-10-53. Review.

14.

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, Gentilcore G, Capone M, Mozzillo N, Rozzo C, Cossu A, Tanda F, Palmieri G.

Oncol Rep. 2011 Jun;25(6):1495-502. doi: 10.3892/or.2011.1220. Epub 2011 Mar 18.

PMID:
21424129
15.

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.

Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N.

J Transl Med. 2010 Aug 16;8:76. doi: 10.1186/1479-5876-8-76.

16.

Main roads to melanoma.

Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA.

J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86. Review.

17.

NEMO-binding domain peptide inhibits proliferation of human melanoma cells.

Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, De Maio A, Ombra M, Gentilcore G, Capone M, Ascierto M, Satriano RA, Farina B, Faraone-Mennella M, Ascierto PA, Ialenti A.

Cancer Lett. 2009 Feb 18;274(2):331-6. doi: 10.1016/j.canlet.2008.09.038. Epub 2008 Nov 11.

PMID:
19004544

Supplemental Content

Loading ...
Support Center